Editing AUA: Overactive Bladder (2019) (section)

=== General Principles ===
* '''Provide education to patients regarding''' 
**'''Normal lower urinary tract function''' 
**'''What is known about OAB''' 
**'''Benefits vs. risks/burdens of the available treatment alternatives''' 
*'''<span style="color:#ff0000">Counsel patients that OAB</span>''' 
**'''<span style="color:#ff0000">Has a variable and chronic course</span>'''  
**'''<span style="color:#ff0000">Most OAB treatments improve patient symptoms but are unlikely to eliminate all symptoms</span>''' 
**'''<span style="color:#ff0000">Acceptable symptom control may require trials of multiple therapeutic options before it is achieved, with no single ideal treatment, and treatments vary in invasiveness, risk of AEs and reversibility.'''
*** OAB may compromise QoL but generally does not affect survival. A treatment plan, therefore, should carefully weigh the patient’s potential benefit of a particular treatment against that treatment’s risk for, severity and reversibility of AEs.
***Treatment failure occurs when the patient with reasonable expectations does not have the anticipated symptom improvement or is unable to tolerate the treatment due to AEs; lack of efficacy and the presence of intolerable AEs reduce compliance
*'''<span style="color:#ff0000">New treatments should persist for a sufficient duration to achieve (4 to 8 weeks for medications and 8 to 12 weeks for behavioral therapies) clarity regarding efficacy and adverse events for a particular therapy</span> before abandoning the therapy prematurely or before adding a second therapy.'''
**If a comprehensive evaluation has demonstrated that the patient has signs and symptoms consistent with the OAB diagnosis and a particular therapy is not efficacious after a reasonable trial, then an alternative therapy should be tried.